Silver Book Fact

Drugs like bevacizumab- designed to impede the growth of blood vessels and tumors- can cost more than $100,000 per patient. 

Ubel, Peter A., Scott R. Berry, Eric Nadler, Chaim M. Bell, Michael A. Kozminski, Jennifer A. Palmer, William K. Evans, Elizabeth L. Strevel, and Peter J. Neumann. In A Survey, Marked Inconsistency In How Oncologists Judged Value Of High-Cost Cancer Drugs In Relation To Gains In Survival. Health Aff. 2012; 31(4): 709-717. http://content.healthaffairs.org/content/31/4/709.abstract

Reference

Title
In A Survey, Marked Inconsistency In How Oncologists Judged Value Of High-Cost Cancer Drugs In Relation To Gains In Survival
Publication
Health Aff
Publisher
Project HOPE
Publication Date
2012
Authors
Ubel, Peter A., Scott R. Berry, Eric Nadler, Chaim M. Bell, Michael A. Kozminski, Jennifer A. Palmer, William K. Evans, Elizabeth L. Strevel, and Peter J. Neumann
Volume & Issue
Volume 31, Issue 4
Pages
709-717
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Economic Value

Related Facts

  • The 1-year survival rate for lung cancer has increased from 37% in 1975 to 42% in 1999-2001, largely because of improvements to surgical techniques and with combined therapies.  
  • Use of a monocolonal antibody with adjuvant chemotherapy in HER2+ individuals with operable cancer was associated with a 33 percent reduction in risk of death.  
  • There are nearly 14.5 million people in the U.S. living with a history of cancer.  
  • Thousands of potential cancer medicines in development
     
  • Approximately one third of men diagnosed with prostate cancer will opt for surgical treatment.